Objective To correlate disease course and complications in children with juvenile dermatomyositis (JDM) and polymyositis (JPM) with specific features of muscle pathology on biopsy.Methods This is a retrospective cohort analysis of 59 children diagnosed with JDM or JPM between 1965 and 1998 andfollowed at the Cincinnati Children's Hospital Medical Center (CCHMC) for a mean duration of 7.3 years (range 1.1-24.5 years). Disease course was characterized as limited, chronic non-ulcerative or chronic ulcerative, similar to previously defined disease course subtypes reported by Crowe et al. (1). All subjects had diagnostic muscle biopsies performed at CCHMC and had disease for at least two years' duration in order to classify their disease course as either limited or chronic. Features of muscle histopathology that were evaluated included loss of the intramuscular capillary bed, infarct, perifascicular myopathy, direct immunofluorescence (DIF) staining of the intramuscular vasculature and specifically, the locale of DIF staining, i.e., small arteries or capillaries. Disease complications that were assessed included calcinosis, contractures, muscle atrophy, lipodystrophy, gastrointestinal ulceration, cutaneous ulceration and death. Data analysis was completed using Chi-square or Fisher's exact tests and logistic regression modeling.Results Twenty-two children (37%) had limited disease, 24 (41%) had chronic non-ulcerative disease and 13 (22%) had chronic ulcerative disease. Neither loss of the intramuscular capillary bed nor perifascicular myopathy on muscle biopsy significantly correlated with disease course or the various complications evaluated in this study. DIF staining of intramuscular vessels overall was not significantly associated with clinical disease course, but the localization of DIF staining to intramuscular arteries (rather than to capillaries) was significantly associated with the outcome of chronic ulcerative disease. Nine of the 13 children with chronic ulcerative disease had DIF-arterial staining on muscle biopsy (69%), significantly greater than DIF-arterial staining in children with limited disease (32% had DIF-arterial staining) (p = 0.04), chronic nonulcerative disease (8% had DIF-arterial staining) (p = 0.0002), and non-ulcerative disease overall (limited + chronic nonulcerative disease groups combined) (20% had DIF-arterial staining), with p = 0.001. Additionally, lack of DIF-arterial staining on biopsy was significantly correlated with patients not having gastrointestinal ulceration (p = 0.002), cutaneous ulceration (p = 0.004) andlor death (p = 0.02) as disease-related complications. Infarct on muscle biopsy was significantly associated with the development of chronic ulcerative disease (p = 0.02), being present on biopsy in 23% of children with chronic ulcerative disease compared with none of the patients with chronic non-ulcerative disease and 4% of those with limited disease. Infarct on muscle biopsy correlated with the outcomes of death (p = 0.01) and gastrointestinal ulceration (p 0. 03), but not with the development of cutaneous ulceration (p = 0. 18).Conclusions DIF-arterial staining and infarct on muscle biopsy are significantly associated with the development of chronic ulcerative disease in JDM and JPM, while perifascicular myopathy and loss of the intramuscular capillary network are not associated with disease course. The presence of DIF-arterial staining and infarct on biopsy should suggest early use of second-line therapeutic agents to more quickly bring disease activity under control.

OBJECTIVE:To develop, validate, and determine the measurement characteristics of a quantitative tool for assessing the severity of muscle involvement in children with idiopathic inflammatory myopathies.METHODS:The Childhood Myositis Assessment Scale (CMAS) was developed from 2 existing observational functional assessment tools to assess muscle function in the areas of strength and endurance across a wide range of ability and ages. The 14 ordinal items included were chosen to assess primarily axial and proximal muscle groups and are ranked with standard performance and scoring methods. Following the development of the CMAS, a training video and written instructions were developed and reviewed by the physicians participating in this study. Subsequently, utilizing a randomized block design, 12 physicians independently scored 10 children (9 with dermatomyositis, 1 with polymyositis; ages 4-15 years) twice in one day (morning and afternoon) on the CMAS. A pediatric physical therapist performed quantitative manual muscle strength testing (MMT) twice on each child (morning and afternoon), including the neck, trunk, and proximal and distal extremity muscle groups.RESULTS:The CMAS has a potential range of 0-51, with higher scores indicating greater muscle strength and endurance. The observed mean for the 10 patients was 36.4 (median 44, SD 14.1, observed range 5-51). The total score for the CMAS correlated with the physician's global assessment (by visual analog scale) of disease activity, the MMT score, serum creatine kinase level, and the Juvenile Arthritis Functional Assessment Report score. The score on the CMAS was not correlated with patient age. Interrater reliability (Kendall's coefficient of concordance) ranged from 0.77 to 1.0 for individual items (all P < 0.001), and overall, it was 0.95 (P < 0.001). Intrarater reliability for the individual physicians was measured by correlation of the CMAS scores for each patient on 2 separate evaluations and ranged from 0.97 to 0.99, with an overall correlation for all physicians of 0.98 (all P < 0.001).CONCLUSION:The CMAS demonstrated an acceptable range of observed scores, excellent convergent validity, and excellent inter- and intrarater reliability. The CMAS is validated to quantitatively assess muscle function in the areas of strength and endurance in children with idiopathic inflammatory myopathies. It can be used in routine clinical care as well as therapeutic trials.

OBJECTIVE:To study the frequency of autoantibodies to the 45 kDa DEK nuclear antigen, a putative oncoprotein, in a sample of patients with juvenile rheumatoid arthritis (JRA), and to make correlations with disease subtype and complications such as iridocyclitis. Class I and Class II HLA associations with reactivity to the antigen were also sought.METHODS:Sera from 146 HLA typed patients with JRA representing all subtypes were analyzed for reactivity with the 45 kDa DEK protein by immunoblotting. The antigen was purified to near homogeneity from nuclei of HeLa cells.RESULTS:Antibodies to DEK were found in 57% of all patients with JRA compared to 3% of controls (p < 0.0001). Antibodies were detected more frequently in pauciarticular onset (78%) than in polyarticular onset patients (29%; p < 0.01) and controls (3%; p < 0.0001). 97% of patients with JRA (regardless of onset subtype) and iridocyclitis had anti-DEK antibodies compared to 47% of patients without eye disease (p < 0.0001). Anti-DEK antibodies were found more frequently in females compared to males in the pauciarticular onset disease group (84 vs 42%; p < 0.01). The occurrence of anti-DEK antibodies was closely associated with positive antinuclear antibody serology, and a strong association with the Class I gene HLA-A2 was also observed.CONCLUSION:Antibodies to the 45 kDa DEK protein are characteristic of the pauciarticular onset subtype of JRA, particularly in patients with a history of iridocyclitis. The occurrence of anti-DEK antibodies is significantly but paradoxically associated with the presence of the HLA-A2 allele in such patients.

OBJECTIVE To assess the long-term health outcomes and quality of life of patients with juvenile rheumatoid arthritis (JRA) using health and functional assessment questionnaires in 2 populations, one from the USA and one from Italy. METHODS Patient eligibility criteria: (1) first examined in our units between 1958 and 1990 during the first 6 months after onset of symptoms, (2) diagnosis of JRA by the American College of Rheumatology criteria, (3) disease duration of at least 5 years at the time of assessment of outcome. Instruments used: (1) the Health Assessment Questionnaire (HAQ, short form, or childhood HAQ (CHAQ), and (2) Quality of Life Scales (QOLS, adults only). Eligible patients were identified by computer search and chart review and were then mailed a packet containing a consent/assent form and the assessment instruments. RESULTS Of 346 patients who met the eligibility criteria were able to locate 301, and 290 verbally agreed to participate and were mailed packets. Signed consent and complete information were received from 227 of the 290 (78%), 178 from the USA and 49 from Italy. Mean duration of disease at the time of outcome assessment was 15 yrs. 127 had pauciarticular, 55 polyarticular, and 45 systemic onset disease. Mean and (median) scores of the outcomes are shown in the table. [table: see text] CONCLUSION Long-term outcome, as assessed by the instruments used, is very favorable in most patients with JRA 5 years or more after onset of symptoms.

OBJECTIVE To determine if the germ line gene VH4-34 (VH4.21) encodes the antimonophosphoryl lipid A (MPL) polyspecific antibodies found in oligoarticular arthritis of childhood. METHODS Sera from a range of rheumatic diseases of childhood were assayed for VH4-34 derived antibodies by ELISA using the antiidiotype monoclonal antibody 9G4. Results were compared to assays for anti-MPL antibodies, C4d, and Bb, and for HLA type, joint count, and sedimentation rate. RESULTS VH4-34 derived antibodies were elevated in all diseases studied except rheumatoid factor positive polyarticular disease. In oligoarticular arthritis, VH4-34 gene expression correlated with C4d concentration, and VH4-34 encoded globulins were more concentrated in synovial fluid than in blood. No association was found with HLA type. An association between VH4-34 expression and IgG anti-MPL was found in sera from patients from Cincinnati but not from Stanford. No other evidence supported a direct association between VH4-34 derived and anti-MPL antibodies in these children. CONCLUSION The expression of VH4-34 is increased in several rheumatic diseases of childhood, but, as in adults, not in rheumatoid arthritis. VH4-34 expression is not associated with HLA type. The polyspecific autoantibody nature of some VH4-34 derived antibodies may explain the wide range of the unusual antibodies found in oligoarticular arthritis.

To determine whether genetic markers for chronic iridocyclitis could be identified, we used both serologic and oligonucleotide dot blot techniques to characterize immunogenetically 164 children with early-onset pauciarticular juvenile rheumatoid arthritis. Seventy-eight children (47.6%) had chronic iridocyclitis and 86 (52.4%) had not had evidence of eye disease during a mean follow-up period after the onset of arthritis of 15.8 years (minimum of 5.5 years). Control subjects were 218 healthy, unrelated individuals. The analysis was limited to alleles known to be associated with an increased or decreased risk of early-onset pauciarticular juvenile rheumatoid arthritis or of chronic iridocyclitis in this form of juvenile rheumatoid arthritis. Only one split of human leukocyte antigen (HLA)-DR5, HLA-DRB1* 1104, showed a statistically significant association with a risk of chronic iridocyclitis (chi-square value = 7.52; p = 0.036 adjusted; odds ratio 3.45); HLA-DQA1* 0501 and HLA-DQB1* 0301, both in linkage disequilibrium with HLA-DRB1* 1104, also were significantly associated with eye disease. Patients with both the DRB1* 1104 and DPB1* 0201 genes had a 7.7-fold increased risk for chronic iridocyclitis compared with that for other patients. The presence of HLA-DRB1* 1104 was about four times as specific, but only about one third as sensitive, as antinuclear antibodies in identifying patients at risk for eye disease. Although all children with early-onset pauciarticular juvenile rheumatoid arthritis should undergo periodic slit-lamp examinations, those with the HLA class II gene DRB1* 1104 are at particularly high risk for eye disease, and we recommend that they be monitored carefully for its evolution.

The suggestion is heard, with increasing frequency, that the therapeutic pyramid be dismantled and that medical management be reordered to treat juvenile rheumatoid arthritis as early and as decisively as possible to induce prompt remission of disease, thereby preserving function and the quality of life. We scrutinize paradigms that guide our treatment strategies, review current practices, update data derived from those practices, and propose reassessment for treatment in the 1990s.

In a cohort of 72 patients with iridocyclitis (iritis) and early onset pauciarticular juvenile rheumatoid arthritis (EOPA-JRA) the course of the eye disease was matched with ocular outcome. Chronicity of inflammation (greater than 6 months/episode) was correlated with complications of eye disease that caused impairment of vision. HLA antigens in these patients were compared with the HLA antigens in a cohort of 77 patients with EOPA-JRA in whom iridocyclitis had failed to develop over a followup of 5 years or longer. HLA-DR5 (11) was correlated with the presence of eye disease, and HLA-DR1 with its absence; HLA-DRw8, which strongly predisposes to EOPA-JRA, was neutral with respect to eye disease.

The risk of iridocyclitis in children with early onset pauciarticular juvenile rheumatoid arthritis (EOPA-JRA) has been shown to be associated with certain HLA haplotypes. Our report contains an actuarial analysis, using one-year intervals, of 161 subjects and estimates haplotype specific risks. Individuals who possess the major susceptibility haplotype HLA-DR5 (11) developed eye disease earlier and with a greater frequency than did those with the protective HLA-DR1 haplotype. Highly significant differences were found between the resulting life-table curves for HLA-DR5 and HLA-DR1 positive subjects (p = 0.00003). These time oriented risk estimates may aid clinicians in determining more precisely the probability of iridocyclitis throughout the course of the disease in children with EOPA-JRA.

Arthritis & RheumatismVolume 33, Issue 4 p. 587-590 ArticleFree to Read Advanced drug therapy in juvenile rheumatoid arthritis Christos A. Gabriel MD, Christos A. Gabriel MD Clinical and Research Fellow in Pediatric Rheumatology, Children's Hospital Medical Center Children's Hospital Medical Center, Special Treatment Center for Juvenile Arthritis, Cincinnati, Ohio.Search for more papers by this authorJoseph E. Levinson MD, Corresponding Author Joseph E. Levinson MD Professor Emeritus of Medicine and Pediatrics, University of Cincinnati College of Medicine and Children's Hospital Medical Center Children's Hospital Medical Center, Special Treatment Center for Juvenile Arthritis, Cincinnati, Ohio.Children's Hospital Medical Center, Special Treatment Center for Juvenile Arthritis, Elland and Bethesda Avenues, Cincinnati, OH 45229–2899Search for more papers by this author Christos A. Gabriel MD, Christos A. Gabriel MD Clinical and Research Fellow in Pediatric Rheumatology, Children's Hospital Medical Center Children's Hospital Medical Center, Special Treatment Center for Juvenile Arthritis, Cincinnati, Ohio.Search for more papers by this authorJoseph E. Levinson MD, Corresponding Author Joseph E. Levinson MD Professor Emeritus of Medicine and Pediatrics, University of Cincinnati College of Medicine and Children's Hospital Medical Center Children's Hospital Medical Center, Special Treatment Center for Juvenile Arthritis, Cincinnati, Ohio.Children's Hospital Medical Center, Special Treatment Center for Juvenile Arthritis, Elland and Bethesda Avenues, Cincinnati, OH 45229–2899Search for more papers by this author First published: April 1990 https://doi.org/10.1002/art.1780330419Citations: 2AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1. Giannini EH, Brewer EJ Jr, Kuzmina N, Shaikov A, Wallin B, For the USA Pediatric Rheumatology Collaborative Study Group and the USSR Cooperative Children's Study Group: Auranofin in the treatment of juvenile rheumatoid arthritis: results of the USA-USSR double-blind, placebo-controlled trial. Arthritis Rheum 33: 466–476, 1990 10.1002/art.1780330402 CASPubMedWeb of Science®Google Scholar 2. Brewer EJ, Giannini EH, Person DA: Juvenile Rheumatoid Arthritis. Second edition. Philadelphia, WB Saunders, 1982 Google Scholar 3. Dequeker J, Mardjuadi A: Prognostic factors in juvenile chronic arthritis. J Rheumatol 9: 909–915, 1982 CASPubMedWeb of Science®Google Scholar 4. Levinson JE, Balz GP, Bondi S: Gold therapy. Arthritis Rheum 20: 531–535, 1977 CASPubMedGoogle Scholar 5. Brewer EJ, Giannini EH, Kuzmina N, Alekseev L: Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis. N Engl J Med 314: 1269–1276, 1986 10.1056/NEJM198605153142001 CASPubMedWeb of Science®Google Scholar 6. Brewer EJ Jr, Giannini EH, Barkley E: Gold therapy in the management of juvenile rheumatoid arthritis. Arthritis Rheum 23: 404–411, 1980 10.1002/art.1780230403 PubMedWeb of Science®Google Scholar 7. Giannini EH, Brewer EJ, For the Pediatric Rheumatology Collaborative Study Group: Methotrexate in the treatment of recalcitrant JRA: results of the double-blind, placebo controlled, randomized trial (abstract). Arthritis Rheum 33 (suppl 4): S82, 1989 Google Scholar 8. Wilske KR, Healey LA: Remodeling the pyramid: a concept whose time has come. J Rheumatol 16: 565–567, 1989 PubMedWeb of Science®Google Scholar 9. Hess EV, Luggen ME: Remodeling the pyramid: a concept whose time has not come. J Rheumatol 16: 1175–1176, 1989 CASPubMedWeb of Science®Google Scholar 10. Grondin C, Malleson P, Petty RE: Slow-acting antirheumatic drugs in chronic arthritis of childhood. Semin Arthritis Rheum 18: 38–47, 1988 10.1016/0049-0172(88)90033-9 CASPubMedWeb of Science®Google Scholar 11. Ozdogan H, Turunc M, Deringol B, Yurdakul S, Yazici H: Sulphasalazine in the treatment of juvenile rheumatoid arthritis: a preliminary open trial. J Rheumatol 13: 124–125, 1986 CASPubMedWeb of Science®Google Scholar 12. Dale I: The treatment of juvenile rheumatoid arthritis with azathioprine. Scand J Rheumatol 1: 125–127, 1972 10.3109/03009747209103011 CASPubMedGoogle Scholar 13. Walters D, Robinson RG, Dick-Smith JB, Corrigan AB, Webb J: Poor response in two cases of juvenile rheumatoid arthritis to treatment with cyclophosphamide. Med J Aust 1070, 1972 Google Scholar 14. Ostensen M, Hoyeraal HM, Kass E: Tolerance of cyclosporine A in children with refractory juvenile rheumatoid arthritis. J Rheumatol 15: 1536–1538, 1988 CASPubMedWeb of Science®Google Scholar 15. Palmer RG, Varonos S, Dore CJ, Denman AM, Ansell BM: Chlorambucil induced chromosome damage in juvenile chronic arthritis. Arch Dis Child 60: 1008–1013, 1985 10.1136/adc.60.11.1008 CASPubMedWeb of Science®Google Scholar 16. Palmer RG, Kanski JJ, Ansell BM: Chlorambucil in the treatment of intractable uveitis associated with juvenile chronic arthritis. J Rheumatol 12: 967–970, 1985 CASPubMedWeb of Science®Google Scholar 17. Key SN, Kimura SJ: Iridocyclitis associated with juvenile RA. Am J Ophthalmol 80: 425, 1975 10.1016/0002-9394(75)90529-2 PubMedWeb of Science®Google Scholar 18. Nussenblatt RB: Cyclosporin therapy for endogenous uveitis, Uveitis Update. Edited by KM. Saari. Amsterdam, Excerpta Medica, 1984 Google Scholar 19. Kvien TK, Hoyeraal HM, Sandstad B: Azathioprine versus placebo in patients with juvenile rheumatoid arthritis: a single center double blind comparative study. J Rheumatol 13: 118–123, 1986 CASPubMedWeb of Science®Google Scholar 20. Pernice W, Schuchmann L, Dippell J, Suschke J, Vogel P, Truckenbrodt H, Schindera F, Humburg Ch, Brzoska J: Therapy for systemic juvenile rheumatoid arthritis with γ-interferon: a pilot study of nine patients. Arthritis Rheum 32: 643–646, 1989 10.1002/anr.1780320520 CASPubMedWeb of Science®Google Scholar 21. Levinson JE: Reflections of a pediatric rheumatologist. Rheum Dis Clin North Am 13: 149–155, 1987 CASPubMedWeb of Science®Google Scholar 22. Lindbjerg IBF: Juvenile rheumatoid arthritis: a followup of 75 cases. Arch Dis Child 39: 576–583, 1964 10.1136/adc.39.208.576 CASPubMedWeb of Science®Google Scholar Citing Literature Volume33, Issue4April 1990Pages 587-590 ReferencesRelatedInformation

A juvenile rheumatoid arthritis-like arthropathy has previously been documented in 12 patients with Down syndrome. An additional 9 patients are described and the literature is reviewed. It is unknown whether these patients have juvenile rheumatoid arthritis or a unique arthropathy in light of the genetic and immunologic abnormalities associated with Down syndrome. Most of the patients had a progressive course with polyarticular disease complicated by subluxations and a long lag time to diagnosis. The purpose of reporting these children is to increase awareness of this association and facilitate more appropriate and timely diagnosis of arthritis in Down syndrome patients.

Summer camps for juveniles with rheumatic disease are being offered increasingly as components of comprehensive treatment approaches, but the therapeutic value of these sessions is largely undetermined. This study attempted to judge the impact of a summer camping experience on two aspects of participants' psychosocial functioning, self-concept, and locus of control. Both of these constructs have been related to effective disease management. On both measures, the mean scores of 36 campers improved significantly following a week-long camp session, and these positive effects were maintained over a 6-month follow-up period. Campers who had attended previous camping sessions appeared to obtain maximal benefit, and male campers with rheumatic disease were identified as needing special attention. The study's limitations are discussed, and future research directions are outlined.

Analysis of sex ratio in 301 siblings of 150 patients with early-onset pauciarticular juvenile rheumatoid arthritis revealed a male-to-female ratio of 1:2.00 in sibships with an HLA-B44+ proband, compared with a ratio of 1:1.05 in other sibships (G2 = 6.07, df = 1, p = 0.014). The siblings had a sex ratio of 1:0.8, when the HLA-B44 antigen was present in either parent but not transmitted to the proband. The capacity to distort the sex ratio was limited therefore to disease-associated HLA-B44 haplotypes.

Criteria for the classification of juvenile rheumatoid arthritis were analyzed in a detailed database of 250 children in order to assess the accuracy of diagnosis and validity of onset types and course subtypes. A number of conclusions have been derived from this study: All definitions of the 1973 criteria for classification of juvenile rheumatoid arthritis should be retained. The addition of onset types to the 1976 revision of the criteria has been validated. The course of the disease after the onset period of 6 months is as important to the outcome of a group of children as is the onset type. The current classification should be broadened to include the course subtypes.